Trial Profile
A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to Methotrexate Therapy.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Genmab; GlaxoSmithKline; GSK
- 13 Jan 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 May 2011 Actual initiation date (January 2008) added as reported by ClinicalTrials.gov.
- 12 May 2011 Planned End Date changed from 1 Aug 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.